دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Oncologists in social media—what are the limits?
doi : 10.1016/S1470-2045(22)00227-3
Volume 23, Issue 5, May 2022, Page 553
Should tomosynthesis replace mammography for breast cancer screening?
NehmatHoussamiab
Is tailored systemic therapy in renal cell carcinoma realistic?
TsunenoriKondoa
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer
StanislasQuesadaaWilliamJacota
Long-term versus short-term androgen deprivation combined with EBRT for unfavourable prostate cancer
JuanitaCrooka
Proud about PRADA: radiotherapy before deep inferior epigastric perforator flap reconstruction
OritKaidar-PersonabPhilipPoortmanscd
War-torn Afghanistan and cancer care: where to focus?
Usman AyubAwanaMuhammad WasifMalikbMuhammad SohailAfzalcHaroonAhmeddSarmadZahoore
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint
Nicholas CRichardsonaYvetteKasamonaRichardPazdurabNicoleGormleya
Re-engaging EU citizens with national screening programmes and cancer diagnosis post-pandemic
Anne-MarieBairda
Bridging the equity gap in patient education: the biliary tract cancer BABEL project
RaffaellaCasolinoabChiaraBraconiacd
Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431
EtanOrgelabDoojduenVillalunaeMark DKrailodAdamEsbenshadefgLillianSunghDavid RFreyerabcd
Patient-reported outcomes: what really matters to patients?
ElshadHasanovaJaime O HerreraCaceresbDeborah AMaskenscRachel HGilescAndreas MSchmittde
Patient-reported outcomes: what really matters to patients? – Authors' reply
DavidCellaaToni KChoueiribRobert JMotzerc
Screening for breast cancer brain metastases – Authors' reply
MinYana
The DRUG Access Protocol: access inequality and European harmonisation
Tobias BPolakabcdDavid G JCucchieJoostvan RosmalenbcCarin AUyl-de Groota
The DRUG Access Protocol: access inequality and European harmonisation – Authors' reply
Sahar Barjestehvan Waalwijk van Doorn-KhosrovaniaLaurien JZeverijnbcEmile EVoestbc
Has Pakistan failed to roll back HPV?
Usman AyubAwanaAamer AliKhattaka
A biobank perspective on use of tissue samples donated by trial participants
ValerieSpeirsaAngelaCoxbClaudeChelalacJacqueline AJameseRichard AAdamsdJ LouiseJonesc
Accelerated approval requirements for lurbinectedin
David JBenjaminaVinayPrasadb
Ongoing crisis in Ukraine continues to affect cancer care
Talha KhanBurki
IAEA reviews plan to release treated water from Fukushima
ManjulikaDas
Biden's proposed investment in cancer research sparks concerns
ManjulikaDas
Carcinogenicity of cobalt, antimony compounds, and weapons-grade tungsten alloy
Margaret RKaragasaAmyWangaDavid CDormanaAmy LHallaJingboPiaConsolato MSergiaElaineSymanskiaElizabeth MWardaVictoria HArrandaleaKenichiAzumaaEduardoBrambilaaGloria MCalafaJason MFritzaShojiFukushimaaJoanna MGaitensaTom KGrimsrudaLeiGuoaElsebethLyngea…Mary KSchubauer-Berigana*
Failure to tackle workforce shortages threatens cancer survival progress in England
EmmaWilkinson
Resilience and perseverance under siege: providing cancer care during the invasion of Ukraine
DaryaKizubaNelyaMelnitchoukbAndriyBeznosenkocGalynaShabatdSolomiiaSemeniveLeticiaNogueirafPatricia JWatsongKimBerghEdward JTrapidoiZeldeEspineljJames MShultzk
FDA decisions on new oncological drugs
GuanqiaoLiYangLiuRuyiHeLingSuXiaoyuanChen
FDA decisions on new oncological drugs
David JBenjaminVinayPrasadMark PLythgoe
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study
SeanMcPhailPhDaRuthSwannPhDab†Shane AJohnsonMAb†Matthew EBarclayPhDc†HazemAbd ElkaderMA [SocSc]dRiazAlviMSceAndrianaBarisicMPHfOliverBucherMScgGavin R CClarkBSchNicolaCreightonMAppStatiBoletteDanckertPhDjCheryl ADennyMPHhDavid WDonnellyPhDkJeff JDowdenMSclNorahFinnMScmnColin RFoxMSckSharonFungMScoProfAnna TGavinFFPHMk…HuiYou
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial
ProfWalterHeindelMDa*ProfStefanieWeigelMDa*JoachimGerßDr rer natbProfHans-WernerHenseMDcAlexanderSommerDipl IngaMiriamKrischkeDr rer natdLauraKerschkeDr rer medicbfor the TOSYMA Screening Trial Study Groupâ€
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
Yann-AlexandreVanoMDafRézaElaidiPhDbMostefaBennamounMDgProfChristineChevreauMDiDelphineBorchielliniMDkDianePannierMDlDenisMailletMD3MarineGross-GoupilMDoProfChristopheTournigandMDpacBrigitteLaguerreMDqPhilippeBarthélémyMDsElodieCoquanMDtProfGwenaëlleGravisMDuProfNadineHouedeMDwMathildeCancelMDxOlivierHuillardMDjPhilippeBeuzebocMDyProfLaureFournierMDc…ProfStéphaneOudardMDaagâ€
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
ProfUlrikeNitzMDab*OlegGluzMDabc*MonikaGraeserMDabdProfMatthiasChristgenMDfSherkoKuemmelPhDaghProfEva-MariaGrischkeMDiProfMichaelBraunMDjDorisAugustinMDkJochemPotenbergMDlKatjaKraussMDmClaudiaSchumacherMDnHelmutForstbauerMDoProfToralfReimerMDpAndreaStefekMDqHans HolgerFischerMDrEnricoPelzMDsChristinezu EulenburgPhDaeRonaldKatesPhDa…JokeTio
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial
ProfShigehiraSajiMDaNarutoTairaMDcMasahiroKitadaMDdToshimiTakanoMDeMasahiroTakadaMDfProfTohruOhtakeMDbProfTatsuyaToyamaMDhYuichiroKikawaMDjYoshieHasegawaMDkTomomiFujisawaMDlMasahiroKashiwabaMDmProfTakanoriIshidaMDnRikiyaNakamuraMDoProfYutakaYamamotoMDpProfUhiTohMDqHirojiIwataMDrProfNorikazuMasudaMDiProfSatoshiMoritaPhDg…ProfMasakazuToiMDf
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
ProfSyed AHussainMDaJason FLesterFRCRcRichardJacksonPhDdMatthewGornallBScdMuneebQureshiFRCRaAnthonyElliottPhDeSimon JCrabbPhDfProfRobert AHuddartPhDgNaveenVasudevPhDhProfAlison JBirtleMDiJaneWorldingFRCRjProfNicholas DJamesPhDgOmiParikhFRCRiMariaVilarino-VarelaFRCRkRobertoAlonziMDlMark DLinchPhDmIrbaz BRiazMDnProfJames W FCattoPhDb…ProfRobert JJonesPhDp
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Luis ADiazJrMDaKai-KeenShiuMDbTae-WonKimMDcBenny VittrupJensenMDdLars HenrikJensenMDeCornelisPuntMDfgDenisSmithMDhRocioGarcia-CarboneroMDiManuelBenavidesMDjPeterGibbsMDkChristellede la FourchardiereMDlFernandoRiveraMDmElenaElezMDnDung TLeMDoTakayukiYoshinoMDpWen YanZhongPhDqDavidFogelmanMDrPatriciaMarinelloPharmDr…ThierryAndreMDs
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial
AlmudenaZapateroPhDaAraceliGuerreroMDbXavierMaldonadoPhDcAnaÃ�lvarezMDdCarmen GonzálezSan-SegundoPhDdMarÃa Ã�ngeles CabezaRodrÃguezMDeJosep MarÃaSoléMDfAgustà PedroOlivéMDgFrancescCasasPhDhAnaBoladerasPhDiCarmen MartÃnde VidalesPhDaMarÃa Luisa Vázquezde la TorreMDjSusanaVaraMSckJuan LuisSanzMSckFelipe ACalvoPhDdl
Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study
Paul T RThiruchelvamFRCSa*Daniel RLeffFRCSad*Amy RGoddenMDeSusanCleatorFRCRbSimon HWoodFRCScAnna MKirbyFRCRgNavidJallaliFRCScNavitaSomaiahFRCRgJudith EHunterFRCScFrancis PHenryFRCScAikateriniMichaPhDeRachel LO'ConnellFRCSeKabirMohammedPhDgNeillPataniFRCShMelissa L HTanFRCSiDorothyGujralFRCRbGillianRossFRCRgStuart EJamesFRCSf…Fiona AMacNeill
Equity in national cancer control plans in the region of the Americas
PatrÃciaLoggettoMPPaJulieRitterMPHaKelseyMarxMPHbMonika LMetzgerMD†aCatherine GLamMD†a
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group
GiovanniMoranaMDa†ProfDennisShawMDb†Shannon MMacDonaldMDcClaireAlapetitePhDdThankammaAjithkumarMDfAashimBhatiaMDhHervéBrisseMDeCamiloJaimesMDiThomasCzechMDjProfGirishDhallMDkJasonFangusaroMDlCecileFaure-ConterMDmMaryamFouladiMDnProfDarrenHargraveMDoJulie HHarreldMDpDipayanMitraMDqJames CNicholsonDMgProfMarkSouweidaneMDr…ProfMatthew JMurrayPhDgy
Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials
Mallorie HFieroPhDaJessica KRoydhousePhDcVishalBhatnagarMDbTing-YuChenPhDaBellinda LKing-KallimanisPhDdShenghuiTangPhDaPaul GKluetzMDb
G-CSF-induced carotid inflammation
HarshabadSinghMBBSaceMichael HRosenthalMDbdeBrian MWolpinMDace
